June, 2017

article thumbnail

Effect of Alternate-Day Fasting Among Metabolically Healthy Obese Adults

JAMA Internal Medicine

This randomized clinical trial compares the effects of alternate-day fasting vs daily calorie restriction on weight loss, weight maintenance, and risk indicators for cardiovascular disease.

article thumbnail

How to maximise the value of digital in medtech

pharmaphorum

With a wealth of market and regulatory changes impacting the medtech sector, it’s time for digital technology to steer the direction of your future business. This expert webinar will evaluate how to strategically embed digital within your own organisation and explore the challenges and the opportunities for transforming customer relationships, driving commercial outcomes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CIA Torture as Human-Subjects Research

Research Ethics Blog

In the piece linked below, the author (a professor of sociology at the University of California) argues that modern norms governing human-subjects research are actually stronger, or at least more clear, than those governing government-sanctioned torture. Some of us professionally involved in research ethics governance might not agree that norms of that discipline are beyond debate.

article thumbnail

Commercialization

Syneos Health

At Syneos Health®, we are able to improve brand performance by leveraging data and insights, accumulated best practices and deep access to therapeutic expertise.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Disruption and maturity: the future directions for biologics in healthcare

pharmaphorum

A digital debate analysing the future for biologics in the UK and the factor affecting market access in this territory. Our expert panel will cover a number of key topics including: •Are the savings offered by biosimilars being used to innovate and take advantage of the exciting new biologic technologies or just filling in the NHS potholes? •Will the industry continue to invest in cutting-edge research if the UK is not prepared to fund access to it •In a post-Brexit world how can the UK continue

article thumbnail

Powering pharma’s commercial teams with market access insights

pharmaphorum

Market access is influencing drug development and commercial launch strategy more than ever before, with 85% of prescription drugs in the United States reimbursed through managed care plans. Biopharma companies must take into account a multitude of factors when considering physician prescribing behaviors, and need a more integrated "pull-through" strategy across their teams, from managed markets, to marketing, to field sales.